Phase II Study of Irinotecan and Docetaxel in Patients with Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma.
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Docetaxel (Primary) ; Irinotecan (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 08 Apr 2017 Status changed from active, no longer recruiting to completed.
- 26 Oct 2015 Planned End Date changed from 1 Dec 2015 to 1 Jun 2017, according to ClinicalTrials.gov record.
- 26 Oct 2015 Planned primary completion date changed from 1 Jan 2015 to 1 Jun 2016, according to ClinicalTrials.gov record.